Who Paid My Doc
David Smith
Clinical Cardiac Electrophysiology Reno, NV Medical Doctor
NPI 1487674362 CMS profile 519500
1500 E 2Nd St, Suite 400, Reno, NV 89502
General payments
$10,479
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$2,603
Through program year 2025, David Smith of Reno, NV is reported in the CMS Open Payments database as having received $10,479 across 301 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,603 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 35th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,032 | 95 | |
| 2024 | General | $4,933 | 98 | |
| 2023 | General | $1,382 | 40 | |
| 2022 | General | $1,420 | 32 | |
| 2021 | General | $310 | 8 | |
| 2020 | General | $25 | 1 | |
| 2019 | General | $377 | 27 |
Beside peers
- David Smith
- Clinical Cardiac Electrophysiology median
- Middle half of Clinical Cardiac Electrophysiology
- National median
In program year 2025, general payments to David Smith were reported at $2,032. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.
Show as a table
| Year | David Smith | Clinical Cardiac Electrophysiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $377 | $2,361 | $585–$8,260 | $163 |
| 2020 | $25 | $993 | $247–$4,351 | $114 |
| 2021 | $310 | $1,185 | $326–$4,739 | $132 |
| 2022 | $1,420 | $2,073 | $554–$6,789 | $149 |
| 2023 | $1,382 | $2,568 | $759–$8,159 | $160 |
| 2024 | $4,933 | $2,557 | $703–$7,403 | $164 |
| 2025 | $2,032 | $2,462 | $733–$7,710 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 35 drugsPart D claims
3,257
Drug cost
$1,090,423
Branded share of claims
27.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 372 | $528,256 | |
| Xarelto Rivaroxaban | Brand | 264 | $357,025 | |
| Multaq Dronedarone Hcl | Brand | 25 | $47,459 | |
| Farxiga Dapagliflozin Propanediol | Brand | 20 | $31,037 | |
| Ozempic Semaglutide | Brand | 15 | $24,683 | |
| Flecainide Acetate | Generic | 348 | $23,069 | |
| Entresto Sacubitril/Valsartan | Brand | 15 | $21,071 | |
| Dofetilide | Generic | 62 | $10,783 | |
| Metoprolol Succinate | Generic | 461 | $7,713 | |
| Dabigatran Etexilate Dabigatran Etexilate Mesylate | Brand | 27 | $7,269 |
The 10 drugs with the highest cost, of 35 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 66 billing codesPaid by Medicare
$204,713
Medicare patients
1,672
Services billed
4,195
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Atrial fibrillation | 67% | |
| Arthritis | 46% | |
| Ischemic heart disease | 43% | |
| Heart failure | 42% | |
| Chronic kidney disease | 32% | |
| Diabetes | 31% | |
| COPD | 19% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
301 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Cardiac Electrophysiology in Nevada
Claudio Bonometti
Clinical Cardiac Electrophysiology · Las Vegas, NV
Erik Sirulnick
Clinical Cardiac Electrophysiology · Las Vegas, NV
Niuton Koide
Clinical Cardiac Electrophysiology · Las Vegas, NV
Daejoon Anh
Clinical Cardiac Electrophysiology · Henderson, NV
Jeffrey Turner
Clinical Cardiac Electrophysiology · Carson City, NV
David Navratil
Clinical Cardiac Electrophysiology · Las Vegas, NV
Related records
Clinical Cardiac Electrophysiology in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Cardiac Electrophysiology
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.